{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T08:28:10Z","timestamp":1783067290982,"version":"3.54.6"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Focal segmental glomerular sclerosis (FSGS) is a histologic lesion rather than a specific disease entity and represents a cluster of different conditions affecting both children and adults that includes primary, secondary and genetically mediated forms. These forms can be distinguished by electron microscopy and genetic assessment and show different responsiveness to steroids and immunosuppressants. Despite some promising effects of rituximab in nephrotic syndrome in children, the results in adults with FSGS are disappointing. Our group previously explored the effectiveness of rituximab in eight adult patients with unselected forms of FSGS and achieved a consistent reduction in proteinuria in one case. Following this experience, we developed an alternative therapeutic option intended to enhance the potential of rituximab with the support of other synergic drugs. We herein report the results of this therapeutic protocol (six administrations of rituximab plus two of intravenous cyclophosphamide plus glucocorticoids) in seven prospectively enrolled patients with extensive podocyte effacement and recurrent relapses or steroid dependence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Patients had a median baseline serum creatinine level of 2.2\u00a0mg\/dl (range 1\u20134.7) that decreased to 1.1\u00a0mg\/dl (range 0.9\u20132.2) and 1.1\u00a0mg\/dl (range 0.75\u20132.21) after 3 and 6\u00a0months, respectively, and remained unchanged at 12\u00a0months. Three of five patients with renal failure turned to normal function while the other two patients maintained a stable impairment after 18 and 52\u00a0months. The median proteinuria decreased from 6.1\u00a0g\/24\u00a0h to 3.5, 3.5 and 1.9\u00a0g\/24\u00a0h at 3, 6 and 12\u00a0months, respectively. Specifically, five of seven patients had a partial response at 12\u00a0months and became non-nephrotic. One of them had a complete response at 18\u00a0months and was still in complete remission at the last follow-up visit at 36\u00a0months. Proteinuria persisted unchanged in two of seven patients with a genetic-related disease. No serious late adverse events were observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our results show that intensive B-cell depletion therapy is able to reverse the nephrotic syndrome of steroid-dependent or frequently relapsing adult patients with putatively idiopathic FSGS (i.e. with extensive podocyte effacement).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfac207","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T20:20:10Z","timestamp":1662668410000},"page":"1258-1264","source":"Crossref","is-referenced-by-count":6,"title":["Focal segmental glomerular sclerosis can be effectively treated using an intensive B-cell depletion therapy"],"prefix":"10.1093","volume":"16","author":[{"given":"Dario","family":"Roccatello","sequence":"first","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnet and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital , 10154 Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Baffa","sequence":"additional","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnet and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital , 10154 Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Naretto","sequence":"additional","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnet and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital , 10154 Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Barreca","sequence":"additional","affiliation":[{"name":"Division of Pathology, Citt\u00e0 della Salute e della Scienza Hospital and University of Turin , Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Cravero","sequence":"additional","affiliation":[{"name":"Unit of Nephrology and Dialysis, Ospedale degli Infermi , Biella , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Roscini","sequence":"additional","affiliation":[{"name":"Unit of Nephrology and Dialysis, Casale Monferrato and Novi Ligure Hospitals , Alessandria , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1266-9441","authenticated-orcid":false,"given":"Savino","family":"Sciascia","sequence":"additional","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnet and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital , 10154 Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Fenoglio","sequence":"additional","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnet and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital , 10154 Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"2023073100362104600_bib1","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2215\/CJN.05960616","article-title":"Focal segmental glomerulosclerosis","volume":"12","author":"Rosenberg","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023073100362104600_bib2","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1097\/01.ASN.0000135051.62500.97","article-title":"Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants","volume":"15","author":"Chun","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2023073100362104600_bib3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/ckj\/sfu100","article-title":"Focal and segmental glomerulosclerosis: clinical and kidney biopsy correlations","volume":"7","author":"Sethi","year":"2014","journal-title":"Clin Kidney J"},{"key":"2023073100362104600_bib4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/ndt\/gfu035","article-title":"Focal segmental glomerulosclerosis: towards a better understanding for the practicing nephrologist","volume":"30","author":"Sethi","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2023073100362104600_bib5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41581-021-00427-1","article-title":"Therapeutic trials in adult FSGS: lessons learned and the road forward","volume":"17","author":"De Vriese","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"2023073100362104600_bib6","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1007\/s10067-019-04699-8","article-title":"A comprehensive review of rituximab therapy in rheumatoid arthritis patients","volume":"38","author":"Tavakolpour","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2023073100362104600_bib7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11926-017-0632-1","article-title":"Rituximab in ANCA-associated vasculitis","volume":"19","author":"Hassan","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"2023073100362104600_bib8","first-page":"e19363","article-title":"Management of steroid-resistant nephrotic syndrome in children","volume":"13","author":"Sachdeva","year":"2021","journal-title":"Cureus"},{"key":"2023073100362104600_bib9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000477944","article-title":"High-dose rituximab ineffective for focal segmental glomerulosclerosis: a long-term observation study","volume":"46","author":"Roccatello","year":"2017","journal-title":"Am J Nephrol"},{"key":"2023073100362104600_bib10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ekir.2021.10.017","article-title":"Efficacy of rituximab in treatment-resistant focal segmental glomerulosclerosis with elevated soluble urokinase-type plasminogen activator receptor and activation of podocyte \u03b23 integrin","volume":"7","author":"Hladunewich","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2023073100362104600_bib11","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ekir.2021.01.027","article-title":"A prospective study on long-term clinical outcomes of patients with lupus nephritis treated with an intensified B-cell depletion protocol without maintenance therapy","volume":"6","author":"Roccatello","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2023073100362104600_bib12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3390\/jcm10020292","article-title":"A 3-year observational study of patients with progressive systemic sclerosis treated with an intensified B lymphocyte depletion protocol: clinical and immunological response","volume":"10","author":"Rossi","year":"2021","journal-title":"J Clin Med"},{"key":"2023073100362104600_bib13","doi-asserted-by":"crossref","first-page":"777134","DOI":"10.3389\/fimmu.2022.777134","article-title":"Treating patients with ANCA-associated vasculitis and very severe renal injury with an intensified B cell depletion therapy: comparison with a control cohort receiving a conventional therapy","volume":"13","author":"Roccatello","year":"2022","journal-title":"Front Immunol"},{"key":"2023073100362104600_bib14","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00508-013-0366-7","article-title":"Rituximab in adult patients with multi-relapsing\/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases","volume":"125","author":"Kronbichler","year":"2013","journal-title":"Wien Klin Wochenschr"},{"key":"2023073100362104600_bib15","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2169\/internalmedicine.51.6854","article-title":"Rituximab treatment for adult patients with focal segmental glomerulosclerosis","volume":"51","author":"Ochi","year":"2012","journal-title":"Intern Med"},{"key":"2023073100362104600_bib16","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome","volume":"25","author":"Ruggenenti","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2023073100362104600_bib17","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ckj\/sfaa191","article-title":"Efficacy and safety of rituximab in adult frequent-relapsing or steroid- dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis","volume":"14","author":"Xue","year":"2020","journal-title":"Clin Kidney J"},{"key":"2023073100362104600_bib18","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2215\/CJN.00570109","article-title":"Rituximab treatment of adult patients with steroid- resistant focal segmental glomerulosclerosis","volume":"4","author":"Fernandez-Fresnedo","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023073100362104600_bib19","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/art.24726","article-title":"Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al.","volume":"61","author":"Ramos-Casals","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2023073100362104600_bib20","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/art.24341","article-title":"A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients","volume":"61","author":"Lu","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2023073100362104600_bib21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/ard.2007.079095","article-title":"Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response","volume":"67","author":"J\u00f3nsd\u00f3ttir","year":"2008","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfac207\/46454330\/sfac207.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/8\/1258\/50925840\/sfac207.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/8\/1258\/50925840\/sfac207.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:36:39Z","timestamp":1690763799000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/16\/8\/1258\/6696401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":21,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,9,12]]},"published-print":{"date-parts":[[2023,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfac207","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2022,9,12]]}}}